2016-07-15T17:48:18-05:00 2015-08-31 KPMG LLP 550 S Hope St Suite 1500 Los Angeles CA 90071 990 2014-09-01 453682796 California Institute for Biomedical Research % AMANDA ARELLANO CALI 8582421029 11119 N TORREY PINES RD 100 LA JOLLA CA 92037 PETER G SCHULTZ PRESIDENT 2139724000 2016-07-15 true Chad Franks P01071312 2139724000 2015-07-13 2014 2016-09-27 15:27:22Z PETER G SCHULTZ PHD 11119 N TORREY PINES 100 LA JOLLA CA 92037 67506307 false X WWW.CALIBR.ORG X 2011 THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR) ACCELERATES THE TRANSLATION OF BASIC BIOMEDICAL RESEARCH TO NEW MEDICINES FOR UNMET MEDICAL NEEDS. 5 5 139 0 0 107277 20684 19449181 67448642 102365 16321 885 0 19659708 67485647 0 0 0 0 6780146 9480916 0 0 0 11446894 33969782 18227040 43450698 1432668 24034949 13391411 40255902 8481211 11310753 4910200 28945149 X OUR MISSION IS TO BUILD A UNIQUE INSTITUTE THAT BRIDGES BASIC RESEARCH AND DRUG DISCOVERY, AND THAT ATTRACTS THE BEST AND BRIGHTEST SCIENTISTS, PHYSICIANS AND STUDENTS TO WORK TOGETHER SYNERGISTICALLY TO FIND CURES FOR NEGLECTED HUMAN DISEASES. THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR) IS A BIOMEDICAL RESEARCH ORGANIZATION LOCATED IN SAN DIEGO, CALIFORNIA. CALIBR BRIDGES THE GAP BETWEEN BASIC BIOMEDICAL RESEARCH AND THE CLINICAL APPLICATION OF RESEARCH DISCOVERIES TO HUMAN DISEASE. CALIBR COMMITS SUBSTANTIALLY ALL OF ITS RESOURCES TO BIOMEDICAL RESEARCH ACTIVITIES. CALIBR'S RESEARCH AND WORK WILL CATALYZE THE TRANSLATION OF DISCOVERIES BY SCIENTISTS AT OTHER SAN DIEGO RESEARCH INSTITUTES , AS WELL AS OTHER MAJOR RESEARCH INSTITUTES THROUGHOUT THE WORLD, INTO POTENTIAL NEW THERAPIES FOR MANY LIFE THREATENING AND DEBILITATING DISEASES. THESE DISEASES INCLUDE ORPHAN DISEASES, DEGENERATIVE DISEASES OF AGING, CANCER, AUTOIMMUNE DISEASES, AND INFECTIOUS DISEASES OF THE THIRD false false 40489016 560605 67448642 RESEARCH GRANTS AND CONTRACTS ARE RECEIVED FROM PUBLIC AND PRIVATE INSTITUTIONS AND ARE USED TO CONDUCT BIOMEDICAL RESEARCH. IN THE CURRENT FISCAL YEAR, CALIBR CONDUCTED RESEARCH THROUGH A PRIVATE COLLABORATION AGREEMENT ON AUTOIMMUNE AND INFLAMMATORY DISEASES, CANCER BIOLOGY, CARDIOVASCULAR METABOLIC DISEASES AND NEUROBIOLOGY. IN ADDITION, IT CONDUCTED RESEARCH FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY, JUVENIE DIABETES, PANCREATIC CANCER, MESOTHELIOMA, AND TB DRUG DEVELOPMENT. 40489016 true true false false false false false false false false true false false false true true true false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 21 0 true 139 true false false false false false false false false false false X 5 5 true false false false false false false true true false false true true true true true true false false false CA X AMANDA ARELLANO 8582421029 11119 N TORREY PINES RD SUITE 100 LA JOLLA CA 92037 Peter G Schultz President/BOARD CHAIR 20.0 0.0 X X 0 0 0 Mark Edwards Board Member 1.0 0.0 X 27055 0 0 Isy Goldwater Board Member 1.0 0.0 X 0 0 0 Paul Schimmel Board Member 1.0 0.0 X 27055 0 0 Chris Walsh Board Member 1.0 0.0 X 27055 0 0 Matthew Tremblay Secretary 40.0 0.0 X 169450 0 26250 Amanda Arellano Treasurer (through 6/8/15) 40.0 0.0 X 79377 0 7421 Sabrina Johnson Treasurer (as of 6/9/15) 20.0 0.0 X 0 0 2031 Arnab ChaterJee Director, Medicinal Chemistry 40.0 0.0 X 161112 0 32130 491104 0 67832 2 false true false Cooley LLP 101 California St San Francisco CA 94111 Legal Services 264455 1 20684 20660 20684 Medical Research 541700 67448642 67448642 67448642 18001 18001 0 0 0 0 0 18980 20660 -1680 -1680 -1680 0 0 0 0 67485647 67448642 16321 0 0 0 0 555636 414697 140939 0 7388110 6895153 492957 37513 34776 2737 854956 683591 171365 644701 590424 54277 338545 179680 158865 358806 273767 85039 127095 127095 0 0 0 660507 505285 155222 0 507864 169288 338576 892978 406670 486308 150794 150794 2503559 2217858 285701 97818 42000 55818 0 19602 7832 11770 1153 1153 0 1213624 1199173 14451 68029 68029 COLLABORATION TERMINATION FEE 15000000 15000000 LAB SUPPLIES 6718459 6718459 OUTSOURCED RESEARCH SERVICES 3956630 3737516 219114 SERVICE AGREEMENTS 695411 682104 13307 658908 579949 78959 43450698 40489016 2961682 0 300 300 6490934 30519292 853120 2682559 0 0 0 0 0 0 0 0 0 0 192909 491414 9292471 3204788 5764826 6087683 0 0 0 0 0 0 89322 463419 0 11235 13391411 40255902 895733 2638536 0 0 6698581 7810331 0 0 0 0 0 0 0 0 0 0 886897 861886 8481211 11310753 X 4910200 28945149 0 0 0 0 4910200 28945149 13391411 40255902 24034949 X false true X false false X UC San Diego Medical Center San Diego CA Scripps Memorial Hospital La Jolla La Jolla CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 250772 22057 228715 8993402 3164107 5829295 48297 18624 29673 6087683 0 DEFERRED RENT 861886 861886 X 68461322 975675 975675 67485647 67485647 44426373 975675 975675 43450698 43450698 ADDITIONAL INFORMATION INCOME TAXES: THE INSTITUTE IS A QUALIFIED NONPROFIT ORGANIZATION THAT IS GENERALLY EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND SECTION 23701(D) OF THE CALIFORNIA REVENUE AND TAXATION CODE. THIS EXEMPTION IS FOR ALL INCOME TAXES EXCEPT FOR THOSE ASSESSED ON UNRELATED BUSINESS INCOME (UBI), IF ANY. IN ORDER TO MAINTAIN THAT STATUS, THE INSTITUTE IS PRECLUDED FROM MAKING CERTAIN EXPENDITURES, PRINCIPALLY IN SUPPORT OF POLITICAL PARTIES. MANAGEMENT BELIEVES THAT NO SUCH EXPENDITURES HAVE BEEN MADE. THE INSTITUTE IS NOT A PRIVATE FOUNDATION. THE INSTITUTE ADOPTED ACCOUNTING GUIDANCE RELATING TO ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, WHICH IS PRIMARILY CODIFIED IN FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION 740. THE INSTITUTE FILES A FORM 990 (RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX) ANNUALLY. WHEN THESE RETURNS ARE FILED, IT IS HIGHLY CERTAIN THAT SOME POSITIONS TAKEN WOULD BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHERS ARE SUBJECT TO UNCERTAINTY ABOUT THE MERITS OF THE TAX POSITION TAKEN OR THE AMOUNT OF THE POSITION THAT WOULD ULTIMATELY BE SUSTAINED. EXAMPLES OF TAX POSITIONS COMMON TO THE INSTITUTE INCLUDE SUCH MATTERS AS THE TAX-EXEMPT STATUS OF THE ENTITY AND VARIOUS POSITIONS RELATIVE TO POTENTIAL SOURCES OF UBI. UBI IS REPORTED ON FORM 990-T, AS APPROPRIATE. THE BENEFIT OF TAX POSITION IS RECOGNIZED IN THE FINANCIAL STATEMENTS IN THE PERIOD DURING WHICH, BASED ON ALL AVAILABLE EVIDENCE, MANAGEMENT BELIEVES IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION, INCLUDING THE RESOLUTION OF APPEALS OR LITIGATION PROCESSES, IF ANY. TAX POSITIONS ARE NOT OFFSET OR AGGREGATED WITH OTHER POSITIONS. TAX POSITIONS THAT MEET THE MORE-LIKELY-THAN-NOT RECOGNITION THRESHOLD ARE MEASURED AS THE LARGEST AMOUNT OF TAX BENEFIT THAT IS MORE THAN 50 PERCENT LIKELY TO BE REALIZED ON SETTLEMENT WITH THE APPLICABLE TAXING AUTHORITY. THE PORTION OF THE BENEFITS ASSOCIATED WITH TAX POSITIONS TAKEN THAT EXCEEDS THE AMOUNT MEASURED AS DESCRIBED ABOVE IS REFLECTED AS A LIABILITY FOR UNRECOGNIZED TAX BENEFITS IN THE ACCOMPANYING STATEMENTS OF FINANCIAL POSITION, ALONG WITH ANY ASSOCIATED INTEREST AND PENALTIES THAT WOULD BE PAYABLE TO THE TAXING AUTHORITIES UPON EXAMINATION. AS OF AUGUST 31, 2015 AND 2014, THE INSTITUTE HAS ADDRESSED UNCERTAINTY IN ITS INCOME TAX POSITION UNDER THE GUIDANCE, AND THERE ARE NO UNRECOGNIZED/DERECOGNIZED TAX BENEFITS REQUIRING AN ACCRUAL. FORMS 990 AND 990-T FILED BY THE INSTITUTE ARE SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE UP TO THREE YEARS FROM THE EXTENDED DUE DATE OF EACH RETURN. MANAGEMENT BELIEVES FORMS 990 AND 990-T HAVE BEEN FILED APPROPRIATELY. false false false false false false false false false Matthew Tremblay Secretary 169450 0 0 0 0 0 26250 0 0 0 195700 0 0 0 Arnab ChaterJee Director, Medicinal Chemistry 161112 0 0 0 0 0 32130 0 0 0 193242 0 0 0 Form 990 Part VI Line 2 PRESIDENT AND BOARD MEMBER PETER SCHULTZ SERVES ON A NUMBER OF OTHER CORPORATE BOARDS WITH BOARD MEMBER ISY GOLDWASSER. Form 990 Part VI Line 11b INFORMATION USED TO PREPARE THE FORM 990 WAS COMPILED BY CALIBR'S PERSONNEL. THE RETURN WAS PREPARED WITH THE ASSISTANCE OF ITS PUBLIC ACCOUNTING FIRM. THE FORM 990 WAS REVIEWED BY CALIBR'S AUDIT COMMITTEE, WHICH HAS AUTHORITY AND OVERSIGHT OF CALIBR'S AUDIT AND TAX PREPARATION. A COMPLETE COPY OF THE FORM 990 WAS PROVIDED TO THE FULL BOARD AFTER REVIEW BY THE AUDIT COMMITTEE AND PRIOR TO FILING WITH THE IRS. Form 990 Part VI Line 12c ON AN ANNUAL BASIS, CALIBR DISTRIBUTES CONFLICT OF INTEREST QUESTIONNAIRES WHICH THE BOARD EMBERS, OFFICERS, AND KEY EMPLOYEES COMPLETE AND RETURN. THE PRESIDENT AND VP OF FINANCE AND OPERATIONS REVIEW THE RETURNED FORMS FOR COMPLIANCE. IF A CONFLICT IS DISCOVERED IT IS ESCALATED TO THE APPROPRIATE PARTY WITHIN CALIBR AND THE PERSON RECUSES HIMSELF OR HERSELF FROM THE GOVERNING BODY'S DELIBERATIONS AND DECISIONS IN THE TRANSACTION, AND THE MEETING MINUTES REFLECT THAT THE PARTY IN QUESTION RECUSED THEMSELVES. IN THE EVENT A CONFLICT ARISES THE INDEPENDENT BOARD MEMBERS DISCUSS THE TRANSACTION, THE ALTERNATIVES, AND EVALUATE WHAT IS BEST FOR THE ORGANIZATION. MEETING MINUTES REFLECT THE DISCUSSIONS AND DECISION, INCLUDING WHO VOTED AND WHO WAS RECUSED FROM DISCUSSION AND VOTING. BOARD MEMBERS ARE REQUIRED TO BRING FORTH ANY NEW CONFLICTS OF INTEREST AS THEY ARISE. Form 990 Part VI Line 15a IN ACCORDANCE WITH THE GOVERNING PRINCIPLES OF THE INSTITUTE'S DIRECTOR COMPENSATION POLICY, THE MAXIMUM TOTAL CASH COMPENSATION IS TO BE DETERMINED BY PUBLICLY AVAILABLE DATA AS REVIEWED BY NON-EMPLOYEE, DISINTERESTED MEMBERS OF THE BOARD. THE BOARD ENSURES THAT COMPENSATION OF THE INSTITUTE DIRECTOR SHALL BE REVIEWED NO LESS THAN ONCE IN THREE YEARS BY DISINTERESTED MEMBERS OF THE BOARD. CALIBR'S PRESIDENT IS ELIGIBLE FOR A BASE SALARY FOR PERFORMANCE OF SERVICES IN ANY GIVEN ONE YEAR PERIOD AND SHALL AUTOMATICALLY BE DUE THE BOARD'S PREDETERMINED AND CONTEMPORANEOUSLY APPROVED FAIR AND REASONABLE BASE SALARY, SUBJECT TO AN EXECUTIVE CAP OF $1.05 M PER YEAR. ADDITIONALLY, THE PRESIDENT IS ELIGIBLE TO RECEIVE BONUS INCENTIVE PAY SEPARATE FROM COMPENSATION PAYMENTS IN AMOUNTS DETERMINED BY THE BOARD AT ITS SOLE REASONABLE DISCRETION, PROVIDED THAT SUCH BONUS SHALL NOT CAUSE THE TOTAL COMPENSATION OF EXECUTIVE TO EXCEED THE EXECUTIVE CAP. AT EXECUTIVE'S SOLE DISCRETION, EXECUTIVE MAY WAIVE THE RIGHT TO RECEIVE ALL OR PART OF THE PAYMENTS DUE BEFORE RECEIPT, PROVIDED THAT THE EXECUTIVE GIVES WRITTEN NOTICE TO INSTITUTE OF THE AMOUNT OF PAYMENT(S) WAIVED. IT IS EXPRESSLY UNDERSTOOD BY CALIBR AND EXECUTIVE THAT WAIVER OF PAYMENT(S) SHALL IN NO WAY ALTER OR INFLUENCE INSTITUTE'S FUTURE PAYMENT OBLIGATIONS TO EXECUTIVE OR THE DETERMINATION OR IMPLEMENTATION OF THE EXECUTIVE CAP. THE PRESIDENT HAS WAIVED ANY OTHER FORMS OF COMPENSATION INCLUDING BONUSES AND NON-MONETARY BENEFITS AND PREREQUISITES FOR THE FISCAL YEAR ENDING 08/31/2015. OTHER OFFICER SALARIES ARE DETERMINED BY CALIBR'S PRESIDENT BASED ON COMPARABLE SALARIES FOR INDIVIDUALS HAVING SIMILAR ROLES AND RESPONSIBILITIES AT SIMILAR NON-PROFITS AND BIOTECH COMPANIES. Form 990 Part VI Line 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.